Upending the Medicare Part B Program: The International Pricing Index (IPI) Proposed Model
By Xcenda |
Upending the Medicare Part B Program—The International Pricing Index (IPI) Proposed Model
As demonstrated in other Medicare Part B papers, Xcenda found that providers are not basing treatment decisions based on reimbursement so the question becomes what problem is trying to be solved and are the implications of this demonstration simply creating new problems that the system is ill-equipped to handle. Part B beneficiaries – who often have serious, complex conditions like cancer and rheumatoid arthritis – have the right to access treatments deemed clinically appropriate by their providers. Under the IPI model, vendors with no clinical expertise may have the power to impose restrictions on care and collect revenue as a new middleman in the system. Additionally, the IPI could have a significant impact on pharmaceutical research and development resulting in fewer new drugs for patients.
The paper explores the implications of the model and poses the ultimate question – does the solution solve an existing problem or create new ones.